Divis Laboratories Ltd
₹10037.50
-26.50 (0.26%)
Fri, 06 Nov 2026, 10:05 pm
Divis Laboratories News
Divis Laboratories shares flag large trade on NSE
A large-trade signal flagged approximately 2,13,394 shares of Divis Laboratories on NSE at ₹9,128.50, with a combined value of ₹194.80 crore.
22 Oct 2026
equity-markets
Divis Laboratories shares flag large-trade signal on BSE
A large-trade signal flagged approximately 24,994 shares of Divis Laboratories changing hands on BSE at ₹9400.00, with a combined value of ₹23.49 crore.
30 Sept 2026
equity-markets
Divis Labs accepts retirement of two senior VPs
Divis Laboratories Ltd intimated the retirement of L. Ramesh Babu and D. Madhu Babu as Senior Management Personnel effective July 31, 2026, under SEBI LODR Regulation 30.
31 Jul 2026
companies
Divi's Labs Q1 FY27 Earnings Call Schedule
Divi's Laboratories Limited will host an earnings conference call on August 01, 2026, at 14:00 IST to discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).
24 Jul 2026
companies
Divis Labs cuts carbon footprint in FY26
Divis Laboratories reduced ~13,500 TCO2e emissions and conserved ~1,59,500 KL of water in FY 2025-26. The company validated its net-zero targets by FY 2050.
15 Jul 2026
companies
Market Current News
CONTINENTAL CONTROLS LTD.
Continental Controls rights issue oversubscribed
Continental Controls Limited completed its rights issue of 1.96 crore shares at ₹10 each. The issue was oversubscribed 112.75% and shares list on BSE on November 5, 2026.
05 Nov 2026
ipo
Jivial Industries Limited
Jivial Industries changes IPO machinery vendors
Jivial Industries Ltd approved partial vendor changes for three machinery sets in its IPO project. Costs and timelines remain unchanged despite the switch.
05 Nov 2026
ipo
Antala IPO Day 6: Subscribed 6.43x
Antala Industries IPO sees strong QIB demand at 66.72x on final day. Total subscription reaches 6.43x as Retail and NII interest picks up.
05 Nov 2026
ipo
IGL Spirits lists on BSE and NSE post-demerger
IGL Spirits Limited listed on BSE and NSE on November 4, 2026. The demerged entity reported FY26 revenue of ₹2,801 crore and EBITDA of ₹492 crore.
04 Nov 2026
ipo
Ennature Bio Pharma lists on NSE, BSE
Ennature Bio Pharma Limited listed on NSE and BSE on November 4, 2026. The biopharma division reported ₹246 crore revenue in FY26, driven by branded nutraceuticals.
04 Nov 2026
ipo